What is Can-Fite BioPharma Ltd. (CANF.TA)?

Can-Fite BioPharma Ltd. (CANF.TA) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

Can-Fite BioPharma Ltd. (CANF.TA)

Stock analysis · TLV · Healthcare · Biotechnology

Market Cap

N/A

PE (TTM)

N/A

EPS (TTM)

N/A

Dividend Yield

N/A

Beta

0.02

Day Range

N/A

52-wk Range

N/A

Avg Volume

N/A

Volume

N/A

Can-Fite BioPharma Ltd. (CANF.TA) is a publicly traded company in the Healthcare sector. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Sep 8, 2026

EPS $-1.85 vs est. $-0.50

Missed by $1.35

Proprietary Signals

Signal snapshot temporarily unavailable.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liver inflammatory diseases, and erectile dysfunction. The company's lead investigational compound, Piclidenoson, has progressed through successful completion of its Phase III clinical trial for psoriasis and a Phase II clinical trial for COVID-19. Another promising candidate, Namodenoson, is presently undergoing a Phase III trial for hepatocellular carcinoma and a Phase IIb trial for non-alcoholic steatohepatitis. Furthermore, CF602 is in its pre-clinical phase, with potential application for erectile dysfunction. Beyond drug development, Can-Fite also creates a commercial predictive biomarker blood test kit specifically for A3AR. The company maintains strategic partnerships, including a licensing and collaboration agreement with CMS Medical for the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. A separate collaborative venture with Univo Pharmaceuticals focuses on identifying and jointly developing…